SMMT Stock Risk & Deep Value Analysis
Summit Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on SMMT
We analyzed Summit Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SMMT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈SMMT Performance Overview3yr weekly
Unlock SMMT Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
SMMT Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Medium
About Summit Therapeutics Inc (SMMT)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
large
Market Cap
$14.35B
SMMT Deep Value Analysis
SMMT Research Sources
No external source links for this analysis yet. Run a fresh analysis to capture SEC filings and financial news articles we used.
For educational context only. Not financial advice.
SMMT Red Flags & Warning Signs
- ⚠
Negative HARMONi-3 clinical data
- ⚠
PDUFA delay or complete response letter from FDA for BLA
- ⚠
Continued uncertainty or negative update on China trial (HARMONi-2/HARMONi-6) overall survival data timing
Unlock SMMT Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
SMMT Financial Health Metrics
Market Cap
$14.35B
P/E Ratio
-10.42
Profit Margin
0.00%
Debt-to-Equity
0.03
Dividend Yield
0.00%
Beta (Volatility)
-1.43
Earnings Per Share
$-1.25
SMMT Competitive Moat Analysis
Moat Rating
Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat's durability hinges on the successful clinical development and regulatory approval of ivonescimab, which would grant market exclusivity through patent protection. Its differentiation as a bispecific antibody in a high-need area also strengthens its competitive position.
SMMT Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
SMMT Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings (Expected May 7)
- •HARMONi-3 Interim Data (Q2 2026)
- •PDUFA date for ivonesimab BLA acceptance (November 2026)
Medium-Term (6-18 months)
- •Potential FDA approval for ivonesimab (post-Nov 2026 PDUFA)
- •US/EU Commercial launch preparations for ivonesimab
- •Further clinical trial data for other indications (CRC, head/neck cancer)
Long-Term (18+ months)
- •Ivonescimab market penetration and leadership in 2nd-line NSCLC
- •Pipeline expansion and additional indications for ivonescimab
- •Establishment as a dominant oncology player
Catalysts & Growth Drivers
Sign up free to see growth catalysts
SMMT Bull Case: What Could Go Right
- ✓
Positive outcomes from HARMONi-3 interim data and China OS data releases
- ✓
FDA approval for ivonescimab following the BLA acceptance PDUFA date
- ✓
Updates on commercialization strategy and partnership expansions
Bull Case Analysis
Sign up free to see the bull case
Just analyzed SMMT? Get notified when it moves (one click in-app)
No Telegram required. Alerts show in your bell feed when you return.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Summit Therapeutics Inc (SMMT)?
As of March 24, 2026, Summit Therapeutics Inc has a DVR Score of 8.7 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Summit Therapeutics Inc?
Summit Therapeutics Inc's market capitalization is approximately $14.3B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Summit Therapeutics Inc use?
SMMT is the ticker symbol for Summit Therapeutics Inc. The company trades on the NGM.
What is the risk level for SMMT stock?
Our analysis rates Summit Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of SMMT?
Summit Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -10.4. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Summit Therapeutics Inc's revenue growing?
Summit Therapeutics Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is SMMT stock profitable?
Summit Therapeutics Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the SMMT DVR analysis updated?
Our AI-powered analysis of Summit Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 24, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.